EOLS
Evolus Inc.
$6.18
-$0.07(-1.12%)
52
Overall
40
Value
63
Tech
55
Quality
Market Cap
$411.59M
Volume
383.46K
52W Range
$3.86 - $10.62
Target Price
$15.60
Company Overview
| Mkt Cap | $411.59M | Price | $6.18 |
| Volume | 383.46K | Change | -1.12% |
| P/E Ratio | -8.0 | Open | $6.31 |
| Revenue | $297.2M | Prev Close | $6.25 |
| Net Income | $-51.6M | 52W Range | $3.86 - $10.62 |
| Div Yield | N/A | Target | $15.60 |
| Overall | 52 | Value | 40 |
| Quality | 55 | Technical | 63 |
No chart data available
About Evolus Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest News
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors
TipRanks Clinical-Trials-Auto-Generated Newsdesk•13 days ago
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS)
Brian Anderson•22 days ago
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Evolus (EOLS)
Catie Powers•23 days ago
Evolus Earnings Call Highlights Profitable Growth Path
TipRanks Auto-Generated Newsdesk•23 days ago
Evolus Ends ATM Facility After Strong Q1 Momentum
TipRanks Auto-Generated Newsdesk•23 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EOLS | $6.18 | -1.1% | 383.46K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |